Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Thoracic 1Other hematologic neoplasm 1Breast 1

Conditions

Breast Neoplasms 2046Triple Negative Breast Neoplasms 208Neoplasm Metastasis 133Neoplasms 119Carcinoma, Non-Small-Cell Lung 96Breast Neoplasms, Male 95Ovarian Neoplasms 89Colorectal Neoplasms 70Lung Neoplasms 67Carcinoma, Intraductal, Noninfiltrating 63Melanoma 57Prostatic Neoplasms 55Pancreatic Neoplasms 47Breast Carcinoma In Situ 42Stomach Neoplasms 38Colonic Neoplasms 37Brain Neoplasms 36Carcinoma, Renal Cell 35Inflammatory Breast Neoplasms 33Head and Neck Neoplasms 32Urinary Bladder Neoplasms 29Pain 29Small Cell Lung Carcinoma 27Squamous Cell Carcinoma of Head and Neck 26Endometrial Neoplasms 25Sarcoma 23Fatigue 23Uterine Cervical Neoplasms 21Esophageal Neoplasms 21Multiple Myeloma 18

Interventions

tucatinib 1Trastuzumab 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Meningeal Neoplasms × Breast × Clear all
NCT03501979 2025-08-29

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

University of Alabama at Birmingham

Phase 2 Terminated
17 enrolled 16 charts
Breast

Breast Neoplasms, Meningeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡